Identification of pyroptosis-related signature and development of a novel prognostic model in diffuse large B-cell lymphoma

[1] Aglietti RA(2017)Recent Insights into the Molecular Mechanisms Underlying Pyroptosis and Gasdermin Family Functions Trends Immunol 38 261-271

[2] Dueber EC(2018)NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development Front Immunol 9 2918-47

[3] Ahechu P(2016)TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma Br J Haematol 172 44-1159

[4] Bagratuni T(2020)PD-L1 controls cancer pyroptosis Nat Cell Biol 22 1157-1007

[5] Blasco MT(2020)Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier Blood 135 996-269

[6] Gomis RR(2021)Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress J Hematol Oncol 7 44-25037

[7] Carpio C(2014)A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors J Hematol Oncol 11 e492-687

[8] Chu Y(2021)Pyroptosis, metabolism, and tumor immune microenvironment Clin Transl Med 10 254-4239

[9] Zhou X(2020)Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis Cancer Discov 287 25030-1275

[10] Wang X(2012)Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity J Biol Chem 575 683-21640

[1] Aglietti RA(2017)Recent Insights into the Molecular Mechanisms Underlying Pyroptosis and Gasdermin Family Functions Trends Immunol 38 261-271

[2] Dueber EC(2018)NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development Front Immunol 9 2918-47

[3] Ahechu P(2016)TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma Br J Haematol 172 44-1159

[4] Bagratuni T(2020)PD-L1 controls cancer pyroptosis Nat Cell Biol 22 1157-1007

[5] Blasco MT(2020)Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier Blood 135 996-269

[6] Gomis RR(2021)Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress J Hematol Oncol 7 44-25037

[7] Carpio C(2014)A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors J Hematol Oncol 11 e492-687

[8] Chu Y(2021)Pyroptosis, metabolism, and tumor immune microenvironment Clin Transl Med 10 254-4239

[9] Zhou X(2020)Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis Cancer Discov 287 25030-1275

[10] Wang X(2012)Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity J Biol Chem 575 683-21640